Transcription of STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
{{id}} {{{paragraph}}}
Example: bankruptcy
STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
Working document January 2017. Draft document for comment 1 STABILITY TESTING OF ACTIVE . 2 PHARMACEUTICAL ingredients AND. 3 finished PHARMACEUTICAL PRODUCTS. 4 (January 2017). 5 DRAFT FOR COMMENT. Should you have any comments on the attached text and the STABILITY conditions for WHO Member States (MS) by Region, appendixed to the previous version of this guidance ( ), please send these to: Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, World Health Organization, 1211 Geneva 27, Switzerland; email: fax: (+41 22) 791 4730.
Working document QAS/17.694 page 2 30 SCHEDULE FOR THE PROPOSED ADOPTION PROCESS OF DOCUMENT 31 QAS/17.694: 32 STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS 33 AND FINISHED PHARMACEUTICAL PRODUCTS 34 Development of the proposal to update the guideline for stability testing of active pharmaceutical ingredients and
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: